shRNA targeting long non-coding RNA CCAT2 controlled by tetracycline-inducible system inhibits progression of bladder cancer cells
Metrics: PDF 1497 views | HTML 2602 views | ?
Jianfa Li1,2,*, Chengle Zhuang1,2,*, Yuchen Liu1,*, Mingwei Chen1,3,*, Qing Zhou1, Zhicong Chen1,2, Anbang He1,3, Guoping Zhao4, Yinglu Guo5, Hanwei Wu1, Zhiming Cai1,2,3,5, Weiren Huang1,2,3,5
1Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
2Shantou University Medical College, Shantou, China
3Anhui Medical University, Hefei, China
4Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China
5Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China
*These authors have contributed equally to this work
Weiren Huang, email: [email protected]
Zhiming Cai, email: [email protected]
Keywords: CCAT2, bladder cancer, lncRNAs, tetracycline-inducible, double shRNAs
Received: November 10, 2015 Accepted: March 04, 2016 Published: March 22, 2016
Recent reports show that long non-coding RNAs (lncRNAs) are emerging as significant functional regulators in the development of tumors, including bladder cancer. Here, we found that CCAT2 was upregulated in bladder cancer tissues and cell lines. Through the statistical analyses, we also found that the high expression level of CCAT2 was positively correlated with histological grade and TNM stage of bladder cancer. Further experimental results revealed that knockdown of CCAT2 could decrease cell proliferation and migration as well as induce apoptosis in bladder cancer cells. Besides, using the post-transcriptional device of synthetic biology, we create the tetracycline-inducible double small hairpin RNAs (shRNAs) vector to control the expression level of CCAT2 which was induced by doxycycline in a dosage-dependent manner. In summary, our data indicated that CCAT2 may be an oncogene and a therapeutic target in bladder cancer. The expression of CCAT2 can be quantitatively controlled by the synthetic “tetracycline-on” switch system in bladder cancer in response to different concentrations of doxycycline to inhibit the development of bladder cancer cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.